A proposed nomenclature consensus for the myostatin gene family.
Explore the source record for details and available documents.
Animals↗
Biomedical subjects
Steven B Roberts
Publications and source records attributed to Steven B Roberts.
Development of a real time quantitative PCR assay for the hard clam pathogen Quahog Parasite Unknown (QPX).
Quahog Parasite Unknown (QPX) is a thraustochytrid pathogen responsible for catastrophic mortalities of the northern quahog (hard clam) Mercenaria mercenaria. A real-time quantitative polymerase chain reaction (qPCR) assay was developed to assist research efforts on QPX ecology and pathology. Sensitivity of the assay was evaluated with serial dilutions of QPX-cultured cells to determine the lowest concentration of DNA that remained detectable in both the presence and absence of extraneous environmental substances. QPX cells were quantified before DNA extraction to calibrate standard curves to cell counts. Based on our results, the qPCR assay is able to quantify QPX within the range of 1 to several thousand organisms per reaction. Specificity of the assay was assessed by testing 29 thraustochytrid-like protists isolated from suspension-feeding bivalves from China, Oregon, Maryland, and Virginia. Application of the assay was demonstrated with positive qPCR results from naturally contaminated environmental samples including marine aggregates (i.e. marine snow), clam pseudofeces, and inflammatory nodules from infected clams. This quantitative assay for QPX will provide a valuable tool for characterizing QPX parasite abundances in coastal environments and for improving clam disease diagnostics.
Animals↗
The isolation, characterization, and expression of a novel GDF11 gene and a second myostatin form in zebrafish, Danio rerio.
In the current study, the first non-mammalian growth/differentiation factor (GDF) 11-like homolog was cloned from zebrafish. At the nucleotide level, zebrafish GDF11 is most similar to human GDF11 (79%), while the peptide is most similar to mouse GDF11 (78%). Phylogenetic analysis showed that the zebrafish GDF11 clusters with mammalian GDF11s. This study also cloned a second MSTN form in zebrafish most similar to Salmonid MSTN2 forms. Based on real time PCR, GDF11 is expressed in multiple adult tissues, with levels highest in whole heads and gonads, and expression is less ubiquitous when compared to MSTN expression. During embryonic development, real time PCR demonstrated increasing GDF11 mRNA levels 10 h post-fertilization (hpf), while MSTN mRNA levels remain low until 48 hpf. This is the first report of a transforming growth factor (TGF)-beta superfamily member in a non-mammalian species that is more closely related to GDF11 than MSTN, and also a second form of MSTN in zebrafish; suggesting that a more complex TGF-beta superfamily array exists in primitive vertebrates than previously thought.
Animals↗
Characterization of a myostatin-like gene from the bay scallop, Argopecten irradians.
A complete cDNA was cloned from the bay scallop (Argopecten irradians) that codes for a 382-amino-acid myostatin-like protein (sMSTN). The sMSTN sequence is most similar to mammalian myostatin (MSTN), containing a conserved proteolytic cleavage site (RXXR) and conserved cysteine residues in the C-terminus. Based on quantitative RT-PCR, the sMSTN gene is predominantly expressed in the adductor muscle, with limited expression in other tissues. Using the sMSTN sequence, a Ciona MSTN-like gene was also identified from the Ciona intestinalis genome. These findings indicate that the MSTN gene has been conserved throughout evolution and suggests that MSTN could play a major role in muscle growth and development in invertebrates, as it does in mammals.
Amino Acid Sequence↗
Growth hormone differentially regulates muscle myostatin1 and -2 and increases circulating cortisol in rainbow trout (Oncorhynchus mykiss).
Myostatin (MSTN) negatively regulates muscle growth in vertebrates. Salmonids produce two myostatin transcripts from separate genes. Surprisingly, quantitative analyses indicate different regulatory mechanisms for the two myostatin genes in rainbow trout. MSTN1 mRNA levels were elevated 26% following recombinant bovine growth hormone (rbGH) treatment, while MSTN2 mRNA levels were reduced 74% compared to controls. MSTN precursor protein (42kDa) levels were elevated in rbGH treated fish compared to controls. In addition, circulating cortisol levels were elevated 71% following rbGH treatment compared to controls. In treated and control fish, cortisol levels were elevated 245% at day 0 compared to subsequent days. Treated fish exhibited cortisol levels 207% higher than controls at 0.5 day, and remained at least 50% higher for 7 days following treatment. This pattern of change was positively correlated to MSTN1 mRNA levels. This is the first time a direct relationship has been reported between GH, cortisol, and myostatin. In addition, following rbGH administration, myosin protein concentrations in skeletal muscle samples increased, suggesting that GH regulates expression of the most abundant muscle protein. These results indicate the two myostatin genes are differentially regulated and may possess different functions in rainbow trout muscle, and suggests a possible interaction between GH, cortisol, and muscle growth.
Animals↗
Transgenic salmon overexpressing growth hormone exhibit decreased myostatin transcript and protein expression.
To characterize the role of myostatin (MSTN) in fast growing animals and to examine the relationship between MSTN and growth hormone (GH), MSTN transcript and protein expression were measured in coho salmon overexpressing GH and in wild-type coho salmon. Quantitative real-time RT-PCR and western analysis were used to measure RNA expression of the two salmonid MSTN genes (1 and 2) and levels of MSTN immunoreactive protein (MIP) in developing embryos and adult coho salmon tissues. In transgenic and control coho embryos, MSTN1 and MSTN2 RNA expression were initially observed at about the time of eying, and a 42 kDa MIP was just detected prior to hatching. Expression of the MSTN1 transcript in transgenic salmon was not different from that in wild-type adult coho salmon muscle and brain tissue. However, expression of the MSTN2 transcript was less in white muscle, and greater in red muscle, from transgenic fish compared to wild-type salmon of the same size. Northern analysis revealed that expression of the MSTN2 transcript was less in white muscle from wild-type, age-matched salmon than in transgenic fish. In addition, there was less presumed bioactive MIP in muscle taken from adult transgenic fish compared to controls and evidence of differential protein processing. Decreased MSTN expression in faster growing fish suggests that MSTN does act as a negative regulator of muscle growth in fish, as it does in mammals. The results of this study also suggest that the anabolic effects of GH could be mediated through MSTN.
Analysis of Variance↗
Myostatin protein and RNA transcript levels in adult and developing brook trout.
Quantitative real-time RT-PCR and Western analysis were used to measure RNA expression of the two brook trout myostatin (MSTN) genes ("ovarian", ov and "brain/muscle", b/m), and levels of MSTN immunoreactive protein (MIP) in developing embryos and muscle of brook trout adults. In developing brook trout embryos, ov and b/m MSTN RNAs and MIP significantly increased 45 days post-fertilization. In adult brook trout, the b/m MSTN form was expressed at higher levels in red versus white muscle regardless of gender or time of year. While few changes were observed in MSTN transcripts in fish sampled throughout the year, a significant increase in the processed 14 kDa MIP was observed at spawning in a tissue specific manner, and differences were observed between males and females. These data, along with promoter sequence analysis of the of b/m and ov genes, support a role for MSTN in muscle growth and development in fish.
Amino Acid Sequence↗
Age-related reference ranges for complexed prostate-specific antigen and complexed/total prostate-specific antigen ratio: results from East Texas Medical Center Cancer Institute screening campaign.
The East Texas Medical Center Cancer Institute conducted a regional prostate cancer screening campaign over a 3-year period from 1998 through 2000. Total prostate-specific antigen (tPSA), complexed PSA (cPSA), and cPSA/tPSA ratio (c/tPSA) values were determined. To better define prostate cancer in the population, we chose to determine age-based reference ranges for these PSA isoforms in apparently healthy men. Participants (N = 12,902) between the ages of 20 and 94 were screened and demographic information and serum tPSA and cPSA values were collected across 41 centers throughout East Texas. Men with an abnormal digital rectal examination, a follow-up biopsy indicating prostatic disease, or any clinical signs and symptoms of prostatic disease were excluded. Sera from 7541 evaluable men were tested with the Bayer Immuno 1 PSA and cPSA methods at East Texas Medical Center. The resulting PSA data were then stratified by decade of age to determine age-related reference ranges for each PSA species. The cPSA values increased across all age decades: 40 to 49 years, 1.45 ng/mL; 50 to 59, 1.92 ng/mL; 60 to 69, 2.49 ng/mL; and 70 to 79, 2.77 ng/mL (95th percentile). tPSA levels also increased with age: 1.81 ng/mL, 2.45 ng/mL, 3.17 ng/mL, and 3.57, respectively. Comparatively, the c/tPSA levels remained constant (0.87), regardless of age. The upper limits of tPSA and cPSA values reported here suggest that men should be screened using lower cutoff values than are currently in use. These limits may more accurately identify prostate cancer among otherwise healthy men.
Adult↗